Drug Profile
DCF 987
Alternative Names: Dextran-1; Usherdex; Usherdex-4Latest Information Update: 15 Dec 2009
Price :
$50
*
At a glance
- Originator Polydex Pharmaceuticals
- Developer BCY LifeSciences
- Class Antibacterials; Expectorants; Glucans
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 09 Oct 2007 ALIGN Pharmaceuticals has been acquired by Cyclacel Pharmaceuticals
- 18 May 2007 BCY LifeSciences terminates its licence for DCF 987
- 25 Feb 2005 DCF 987 has been licensed to ALIGN Pharmaceuticals